Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancers

Arcus Biosciences and Gilead Sciences announced that their anti-TIGIT antibody, domvanalimab, failed to meet its primary endpoint in a Phase 3 trial for upper gastrointestinal cancers. This represents another significant setback for the TIGIT class of cancer immunotherapies.